Connection

Kennerly Patrick to Humans

This is a "connection" page, showing publications Kennerly Patrick has written about Humans.
Connection Strength

0.268
  1. Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography. Drug Metab Dispos. 2019 07; 47(7):764-767.
    View in: PubMed
    Score: 0.025
  2. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy. 2019 06; 39(6):677-688.
    View in: PubMed
    Score: 0.024
  3. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct; 27(8):678-689.
    View in: PubMed
    Score: 0.022
  4. Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate. Drug Metab Dispos. 2016 Mar; 44(3):418-21.
    View in: PubMed
    Score: 0.020
  5. Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate. J Clin Psychopharmacol. 2015 Aug; 35(4):464-7.
    View in: PubMed
    Score: 0.019
  6. Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. J Pharm Sci. 2014 Dec; 103(12):3834-3842.
    View in: PubMed
    Score: 0.018
  7. Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug Metab Dispos. 2013 Jan; 41(1):197-205.
    View in: PubMed
    Score: 0.016
  8. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol. 2009 Jan; 24(1):1-17.
    View in: PubMed
    Score: 0.012
  9. Given the multifaceted nature of ADHD, namely its physiologic, cognitive, psychological, and behavioral manifestations, multimodal approaches to treatment are advocated. Introduction. J Clin Psychopharmacol. 2008 Jun; 28(3 Suppl 2):S37-8.
    View in: PubMed
    Score: 0.012
  10. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun; 28(3 Suppl 2):S54-61.
    View in: PubMed
    Score: 0.012
  11. Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 01; 862(1-2):140-9.
    View in: PubMed
    Score: 0.011
  12. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007 Mar; 81(3):346-53.
    View in: PubMed
    Score: 0.011
  13. Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem. 2005 Apr 21; 48(8):2876-81.
    View in: PubMed
    Score: 0.009
  14. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv. 2005 Jan; 2(1):121-43.
    View in: PubMed
    Score: 0.009
  15. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003 Oct; 23(10):1281-99.
    View in: PubMed
    Score: 0.008
  16. Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Clin Pharmacol Ther. 2022 04; 111(4):878-885.
    View in: PubMed
    Score: 0.007
  17. Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. J Clin Psychopharmacol. 2017 Aug; 37(4):419-428.
    View in: PubMed
    Score: 0.005
  18. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos. 2013 Sep; 41(9):1679-85.
    View in: PubMed
    Score: 0.004
  19. Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 01; 879(11-12):783-8.
    View in: PubMed
    Score: 0.004
  20. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008 Jun; 82(6):1241-8.
    View in: PubMed
    Score: 0.003
  21. Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D. Metabolism. 2007 Sep; 56(9):1248-55.
    View in: PubMed
    Score: 0.003
  22. A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15; 858(1-2):91-5.
    View in: PubMed
    Score: 0.003
  23. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec; 16(6):687-98.
    View in: PubMed
    Score: 0.003
  24. Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation. J Pharm Pharmacol. 2005 Oct; 57(10):1365-9.
    View in: PubMed
    Score: 0.002
  25. CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab. 2005 Feb; 90(2):1210-9.
    View in: PubMed
    Score: 0.002
  26. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr; 19(4):680-8.
    View in: PubMed
    Score: 0.002
  27. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003; 42(4):393-401.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.